Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 16/20 | 0.74 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RXRA | P19793 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | VHL | P40337 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090778 | 0.95 | NR1H3 (0.75) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4097553 | 0.92 | NR1H3 (0.87) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4086606 | 0.89 | NR1H3 (0.64) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4097421 | 0.89 | NR1H3 (0.66) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4086922 | 0.89 | NR1H3 (0.66) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4097347 | 0.88 | NR1H3 (0.72) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4086593 | 0.87 | NR1H3 (0.89) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4092248 | 0.87 | NR1H3 (0.65) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL4095145 | 0.86 | NR1H3 (0.80) | NR1H3NR1H2ALDH1A1RXRAMEN1 | |
| SCHEMBL6510569 | 0.85 | NR1H3 (1.00) | NR1H3NR1H2ALDH1A1RXRAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993628-B2 | Synthetic ligands selective for LXRβ over LXRα, identification and methods of use thereof | CITY OF HOPE (US) | 2015-03-31 | — | — | US | disclosed |
| US-20090030082-A1 | SYNTHETIC LIGANDS SELECTIVE FOR LXRbeta OVER LXRalpha, IDENTIFICATION AND METHODS OF USE THEREOF | CITY OF HOPE | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030082-A1 | SYNTHETIC LIGANDS SELECTIVE FOR LXRbeta OVER LXRalpha, IDENTIFICATION AND METHODS OF USE THEREOF | NR1H2, NR1H3, NR1H4 | NR1H3 2/4885NR1H2 1/4885ALDH1A1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.